| Vasant Narasimhan |
Dr. Vasant Narasimhan, MD, is a Chairman at African Parks Network, a Chief Executive Officer at Novartis International AG, a Chief Executive Officer at Novartis AG, a Chief Executive Officer at Novartis Pharma AG, a Chief Executive Officer at Novartis Korea Ltd., a Chief Executive Officer at Novartis Pharma BV, a Chief Executive Officer at Novartis Pharmaceuticals Corp. and a Member at National Academy of Medicine (United States). He is on the Board of Directors at Novartis Foundation and Pharmaceutical Research & Manufacturers of America.
Dr. Narasimhan was previously employed as a Global Head-Development by Sandoz Pharmaceuticals AG, a Global Head-Development by Novartis Pharmaceuticals, a Global Head-Biopharmaceuticals by Sandoz International GmbH, and a Global Head-Development by Novartis Vaccines & Diagnostics, Inc. He also served on the board at Novartis Institute for Functional Genomics, Inc.
He received his undergraduate degree from The University of Chicago, a graduate degree from Harvard Kennedy School of Government and a doctorate degree from Harvard Medical School. |
| Shreeram Aradhye |
Dr. Shreeram Aradhye, MD, is a Chief Medical Officer & President-Development at Novartis AG and a President, Development & Chief Medical Officer at Novartis Pharma AG. He is on the Board of Directors at Valo Health LLC.
Dr. Aradhye was previously employed as a Chief Medical Officer & Executive Vice President by Dicerna Pharmaceuticals, Inc., an Independent Director by Axcella Health, Inc., a Chief Medical Officer by Novartis Pharmaceuticals Corp., a Head-Global Clinical Development & Medical Affairs by Sandoz International GmbH, and an Assistant Professor by University of Pennsylvania.
He received his undergraduate degree from All India Institute of Medical Sciences. |
| Robert Kowalski |
Robert Kowalski is currently the Chief People & Organization Officer at Novartis AG. Prior to this, he held the position of Executive VP & Global Head-Regulatory Affairs at Novartis Pharmaceuticals Corp. from 2009 to 2021. He also served as Senior Vice President & Head-Regulatory Affairs at Novartis Pharma AG from 2015 to 2017. Before his career in the pharmaceutical industry, Kowalski earned undergraduate and doctorate degrees from the University of Wisconsin. |
| Kees Roks |
Kees Roks is currently the Director at Junior Achievement Europe and the Chief Audit Officer at Novartis AG. He completed his undergraduate degree from Technische Universiteit Eindhoven. |
| Karen L. Hale |
Karen L. Hale is currently the Chief Legal Officer at Novartis AG. She is also a member of the Illinois State Bar Association and The Virginia Bar Association. Previously, she worked as the Divisional VP-Commercial Litigation at Abbott Laboratories from 2006 to 2012. She also worked as the Vice President & Deputy General Counsel at AbbVie, Inc. from 2019 to 2021. Prior to that, she was an Associate Attorney at Sidley & Austin. Ms. Hale received her undergraduate degree from Duke University and her graduate degree from The College of William & Mary. |
| Harry Werner Kirsch |
Harry Werner Kirsch is currently holding multiple positions at Novartis Pharma KK, Novartis Vaccines & Diagnostics, Inc., Novartis Institutes for Biomedical Research, Inc., Novartis International AG, and Novartis AG. He previously worked as a Director at GlaxoSmithKline Consumer Healthcare Pte Ltd. and held positions at Procter & Gamble Co. and Novartis Pharma AG. He completed his undergraduate degree at Karlsruher Institut für Technologie. |
| Hans Jörg Reinhardt |
Dr. Hans Jörg Reinhardt is a Vice Chairman at Swiss Re AG, a Chairman at Novartis AG, a Chairman at Novartis Foundation, a Chairman at Novartis, Inc., a Council Member at International Federation of Pharmaceutical Manufacturers, a Chairman at Abadia Retuerta SA, a Chairman at Novartis Finance Corp, a Chairman at Novartis Institutes for Biomedical Research, Inc., a Chairman at Novartis Pharma AG, a Chairman at Novartis Pharma BV, a Chairman at Novartis Pharmaceuticals Corp., a Chairman-Supervisory Board at Novartis International AG, a Chairman-Trustees Board at Institut für molekulare und klinische Ophthalmologie Basel and a Member at Helmholtz-Gemeinschaft Deutscher Forschungszentren eV. He is on the Board of Directors at Swiss Re AG.
Dr. Reinhardt was previously employed as a Chairman-Management Board by Bayer HealthCare AG, a Member-Supervisory Board by MorphoSys AG, a Chairman by Novartis Institute for Functional Genomics, Inc., a Chief Operating Officer by Novartis AG, and a Head-Development by Sandoz Pharmaceuticals AG. He also served on the board at Lonza Group AG and Novartis Institute for Functional Genomics, Inc.
He received his doctorate degree from Universität des Saarlandes. |
| Aharon Gal |
Aharon Gal is currently the Chief Strategy & Growth Officer at Novartis AG since 2022. He is also a Senior Analyst at Sanford C. Bernstein & Co. LLC since 2004. Previously, he worked as a Manager at The Boston Consulting Group, Inc. from 1996 to 2002 and as a Vice President at Canon U.S. Life Sciences, Inc. from 2003 to 2004. Dr. Gal received his undergraduate degree from Emory University and his doctorate degree from Massachusetts Institute of Technology. |
| Klaus Moosmayer |
Klaus Moosmayer currently works at SwissHoldings, as Director, Novartis AG, as Chief Ethics, Risk & Compliance Officer from 2018, and Organisation for Economic Co-Operation & Development, as Member-Executive Board. Dr. Moosmayer also formerly worked at Siemens AG, as Chief Compliance Officer from 2014 to 2018. Dr. Moosmayer received his graduate degree from the University of Freiburg. |
| Simon Brown |
Simon Brown is currently working as the Chief Learning Officer at Novartis AG since 2019. He is also currently serving as a Venture Partner at Emerge Venture Lab Ltd. since 2022. Mr. Brown completed his undergraduate degree from Royal Holloway University of London in 1997. |
| James E. Bradner |
James E. Bradner is the founder of Tensha Therapeutics, Inc. (2011), Acetylon Pharmaceuticals, Inc. (2008), C4 Therapeutics, Inc. (2015), TetraLogic Research & Development Corp. (2008), and Syros Pharmaceuticals, Inc. (2011). He is currently the Chairman at Novartis Institute for Functional Genomics, Inc., Director at Foundation for the National Institutes of Health, Inc. (starting in 2023), Chief Scientific Officer at Amgen, Inc. (starting in 2023), Associate Professor at Harvard Medical School, and Advisor at Longwood Fund Management LLC. His former positions include Associate Director-Therapeutics Science Centre at The Broad Institute, Inc., Member-Supervisory Board at QIAGEN NV (2015), Member at American Chemical Society, Member at American Society of Hematology, and President at Novartis Institutes for Biomedical Research, Inc. (2016-2022). Dr. Bradner received his undergraduate degree from Harvard University in 1994 and his doctorate from Pritzker School of Medicine. |
| Steffen Lang |
Dr. Steffen Lang is a President-Operations at Novartis AG. He is on the Board of Directors at Bachem Holding AG. He received his graduate degree from Ruprecht-Karls-Universität Heidelberg and a doctorate degree from Swiss Federal Institute of Technology. |
| Patrick Horber |
Patrick Horber currently works at AbbVie Pharmaceuticals GmbH, as Managing Director and Novartis AG, as President-International from 2023. Dr. Horber also formerly worked at AbbVie Deutschland GmbH & Co. KG, as Co-Managing Director. Dr. Horber received his graduate degree from the University of Zurich. |
